However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically ...

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work ...

The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple ...